Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy

J Oliva, S Galasinski, A Richey, AE Campbell… - … of Pharmacology and …, 2019 - ASPET
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by misexpression of the
double homeobox 4 (DUX4) developmental transcription factor in mature skeletal muscle …
被引用次数：67 相关文章
[HTML] nih.gov

[HTML][HTML] Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy

J Oliva, S Galasinski, A Richey… - The Journal of …, 2019 - ncbi.nlm.nih.gov
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by misexpression of the
double homeobox 4 (DUX4) developmental transcription factor in mature skeletal muscle …

Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy

J Oliva, S Galasinski, A Richey… - The Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by misexpression of the
double homeobox 4 (DUX4) developmental transcription factor in mature skeletal muscle …

Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

J Oliva, S Galasinski, A Richey… - The Journal of …, 2019 - europepmc.org
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by misexpression of the
double homeobox 4 (DUX4) developmental transcription factor in mature skeletal muscle …

Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy

J Oliva, S Galasinski, A Richey, AE Campbell… - … of Pharmacology and …, 2019 - ASPET
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by mis-expression of the
DUX4 developmental transcription factor in mature skeletal muscle where it is responsible …